13D Filing: Junwei Zheng and Kiwa Bio-Tech Products Group Corp

Item
1. Security and Issuer.

 

The
statement (“Statement”) relates to shares of common stock, par value $0.001 per share (the “Common Stock”),
of Kiwa Bio-Tech Products Group Corporation, a Delaware corporation (the “Issuer” or the “Company”). The
principal executive office of the Issuer is located at 310 N. Indian Hill Blvd., #702, Claremont, California 91711.

 

Item
2. Identity and Background

 

The
Statement is being filed by Junwei Zheng (“Mr. Zheng”) with an address at No. Room 1503, Huicheng Commerce Tower,
No. 839, Xiahe Road, Siming District, Xiamen, Zip 361000, China. Mr.
Zheng is a citizen of the Peoples Republic of China.

 

During
the last five years Mr. Zheng has not (i) been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors); or (ii) been a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction as a result of which proceeding he was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with
respect to such laws.

 

Item
3. Source and Amount of Funds or Other Consideration.

 

Mr.
Zheng acquired
the reported 920,000 shares of the Company’s common stock by purchasing the
shares in a private placement from the Company for an aggregate price of US$1,000,000.00.

 

Item
4. Purpose of Transaction.

 

Mr.
Zheng does
not have any current plans or proposals which
relate to or would result in: (a) the acquisition by Mr. Zheng of additional securities
of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary
corporate transaction, such as a merger, reorganization
or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets
of the Issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer,
including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
(e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s
business or corporate structure; (g) any change in the Issuer’s charter,
bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer
by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease
to be authorized to be quoted in an inter-dealer quotation system of a registered
national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration
pursuant to section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above.